Strategies aimed at modulating hepatic GRK2 activity and restoring the LKB1/AMPK/Akt/eNOS pathway may provide novel opportunities to ameliorate endothelial dysfunction in obesity-related cardiometabolic diseases. This evidence concerns the gene GRK2 and obesity due to melanocortin 4 receptor deficiency.